Literature DB >> 25290217

Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen.

R B Herberman1, J Hiserodt1, N Vujanovic1, C Balch2, E Lotzova2, R Bolhuis3, S Golub4, L L Lanier5, J H Phillips5, C Riccardi6, J Ritz7, A Santoni8, R E Schmidt9, A Uchida10.   

Abstract

Leukocytes in blood and spleen can be activated by interleukin 2 (IL-2) to become cytotoxic to certain tumor cell lines in vitro. Recent evidence suggests that such lymphokine-activated killer (LAK) cells can bring about the regression of solid tumors in animals and patients, under certain circumstances. Here, Ronald Herberman and colleagues from eight international laboratories, review what is known of the characteristics of LAK cell activity and conclude that most of it can be attributed to natural killer cells stimulated by IL-2.
Copyright © 1987. Published by Elsevier B.V.

Entities:  

Year:  1987        PMID： 25290217     DOI： 10.1016/0167-5699(87)90035-1

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  41 in total

1.  Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.

Authors:  R A Rasmussen; S L Counts; J M Lambert; A R Collinson
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA.

Authors:  H R Hubbell; G D Gibson; R D Bigler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels.

Authors:  P Basse; R B Herberman; M Hokland; R H Goldfarb
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Local and regional immunotherapy of cancer with interleukin 2.

Authors:  J Bubeník
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 5.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

Review 6.  Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.

Authors:  Richard D Lopez
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.

Authors:  P M Anderson; F H Bach; A C Ochoa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.

Authors:  M Nagarkatti; P S Nagarkatti; A M Kaplan
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Authors:  M Toledano; C Mathiot; J Michon; G Andreu; D Lando; M Brandely; W H Fridman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.